News

We're creating a lot of buzz. See what we're up to.

Merz North America (Merz Aesthetics, Inc. and Merz Pharmaceuticals, LLC) Announces the End of Court-Ordered Injunction
Read More
Merz Aesthetics, Inc. and Merz Pharmaceuticals, LLC Commit To Full Remediation Compliance In Allergan Inc. Lawsuit
Read More
Merz Aesthetics announces FDA approval of Asclera® (polidocanol) injection, first sclerosant to treat small varicose veins in 60 years.
Read More
Merz Aesthetics' survey shows women look for the next best thing in aesthetics.
Read More

Events Calendar

We partner with doctors to provide ongoing support for our products. We would like the opportunity to meet you in person, shake your hand, thank you for selecting our products, and introduce you to all of our product and service offerings. Visit us at the following meetings and events.

May, 2013

May 24 - 27 Florida Society of Dermatology and Dermatologic Surgery Boca Raton, FL

May 30 - 01 Vascular Annual Meeting San Francisco, CA

May 31 - 02 New England Society of Plastic & Reconstructive Surgeons Newport, RI

RADIESSE® Volumizing Filler

XEOMIN® (incobotulinumtoxinA)

Asclera® (polidocanol) Injection

BELOTERO Balance®

EM00289-09

RADIESSE^® | RADIESSE-FL | RADIESSE^® Voice | XEOMIN^® | Asclera | BELOTERO | Patient Safety | Privacy Policy | Terms of Use | Site Map

Copyright © Merz Aesthetics, Inc. All rights reserved.
The Merz Aesthetics logo is a trademark of Merz Pharma GmbH & Co. KGaA.
RADIESSE is a registered trademark of Merz Aesthetics, Inc.
XEOMIN is a registered trademark of Merz Pharma GmbH & Co. KGaA.
Asclera is a registered trademark of Chemische Fabrik Kreussler & Co. GmbH.
BELOTERO and BELOTERO BALANCE are registered trademarks of Merz Pharma GmbH & Co. KGaA.
Web Site Design by Etna Interactive

WARNING: DISTANT SPREAD OF TOXIN EFFECT
Postmarketing reports indicate that the effects of XEOMIN (incobotulinumtoxinA) for injection, for intramuscular use, and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity but symptoms can also occur in adults treated for spasticity and other conditions, particularly in those patients who have underlying conditions that would predispose them to these symptoms. In unapproved uses, including spasticity in children and adults, and in approved indications, cases of spread of effect have been reported at doses comparable to those used to treat cervical dystonia and at lower doses.

Please see Full Prescribing Information, including Medication Guide for more information.